

8 July 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Posting of Circular and Notice of General Meeting

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, announces further to the announcement on 4 July 2025 relating to its proposed placing to raise £2.0 million (before expenses) ("Announcement"), that it has despatched the Circular and Notice of General Meeting to Shareholders.

The Directors confirm they are to convene a General Meeting of the Company at 11.00 am on Thursday, 24 July 2025, at Windmill House, Innovation Way, York, YO10 5BR.

The Circular and Notice of General Meeting is available on the Company's website at <https://aptamergroup.com/investors/reports-and-presentations>.

The results of voting on all resolutions at the General Meeting will be announced via the Regulatory News Service, and the full results of the voting will be published on the Company's website as soon as practicable after the conclusion of the General Meeting.

- Ends -

For further information, please contact:

Aptamer Group plc	+44 (0) 1904 217 404
Dr Arron Tolley	

SPARK Advisory Partners Limited - Nominated Adviser	+44 (0) 20 3368 3550
Andrew Emmott / Jade Bayat	

Turner Pope Investments (TPI) Limited - Broker	+44 (0) 20 3657 0050
James Pope / Andrew Thacker	

Northstar Communication Limited	+44 (0) 113 730 3896
Sarah Hollins	

About Aptamer Group plc

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the 210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOGBRGDRLGGDGUR